Matthew J. Strauss
Affiliations: | 2016- | Drug Discovery and Biomedical Sciences | University of South Carolina, Columbia, SC |
Google:
"Matthew Strauss"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Strauss MJ, Porter KD, Quizon PM, et al. (2022) Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function. Plos One. 17: e0275182 |
| Zhu J, Quizon PM, Wang Y, et al. (2022) SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice. Neuropharmacology. 109239 |
| Quizon PM, Yuan Y, Zhu Y, et al. (2021) Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology |
| Strauss M, O'Donovan B, Ma Y, et al. (2020) [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Tat Protein. The Journal of Pharmacology and Experimental Therapeutics |
| Sun WL, Quizon PM, Yuan Y, et al. (2019) Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport. Scientific Reports. 9: 3843 |